All In Biotech

Drug Trial Radar · NCT00222053

IFM 99-02 Thalidomide in Myeloma

Last checked: Nov 20, 2026Latest source record: Apr 2, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Apr 2000

Primary completion

Sep 2009

Study completion Dec 2009

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma

Conditions

  • Multiple Myeloma

Interventions

  • ThalidomideDrug

    Per os thalidomide

  • BiphosphonatesDrug

    Biphosphonates

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of responseTime frame: 3 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Médecine Interne, CHU Purpan

    Toulouse, France

  • Médecine Interne, Hôpital Rangueil

    Toulouse, France

  • Rhumatologie, CHU Purpan

    Toulouse, France

  • Rhumatologie, CHU Rangueil

    Toulouse, France

  • Service d'hématologie, CHU Purpan

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.